EGFR-mutated pulmonary adenocarcinoma with concurrent PIK3CA mutation, and with acquired RET fusion and EGFR T790M mutation after afatinib therapy

被引：0
|
作者：
Kim, Minhye [1 ]
Na, Ji Min [1 ]
Lee, Gyeong-Won [2 ]
Lee, Seung Jun [3 ]
Kim, Jong Duk [4 ]
Yang, Jung Wook [5 ]
机构：
[1] Gyeonsang Natl Univ Hosp, Dept Pathol, Jinju, South Korea
[2] Gyeongsang Natl Univ, Div Hematol Oncol, Dept Internal Med, Gyeonsang Natl Univ Hosp,Coll Med, Jinju, South Korea
[3] Gyeongsang Natl Univ, Coll Med, Gyeonsang Natl Univ Hosp, Div Pulmonol & Allergy,Dept Internal Med, Jinju, South Korea
[4] Gyeonsang Natl Univ Hosp, Dept Cardiothorac Surg, Jinju, South Korea
[5] Gyeongsang Natl Univ, Coll Med, Gyeonsang Natl Univ Hosp, Dept Pathol, 79 Gangnam Ro, Jinju 52727, South Korea
来源：
JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE | 2021年 / 55卷 / 01期
关键词：
IMPACT;
D O I：
10.4132/jptm.2020.11.02
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
引用
收藏
页码：79 / 82
页数：4
相关论文
共 50 条
  • [41] Risk Factors for Developing T790M Mutation in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer
    Ouyang, W.
    Xie, C.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E526 - E526
  • [42] Acquired Resistance to Osimertinib by CCDC6-RET Fusion in a Patient with EGFR T790M Mutant Metastatic Lung Adenocarcinoma
    Iams, W.
    Chae, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2249 - S2250
  • [43] Clinical implication and usefulness of de novo EGFR T790M mutation in lung adenocarcinoma with EGFR-tyrosine kinase inhibitor sensitizing mutation
    Lee, Sang Hoon
    Kim, Eun Young
    Kim, Arum
    Chang, Yoon Soo
    CANCER BIOLOGY & THERAPY, 2020, 21 (08) : 741 - 748
  • [44] Benefits of osimertinib treat a lung adenocarcinoma patient with germline EGFR T790M, somatic EGFR 19-Del, TP53 and PIK3CA mutations
    Li, Yingxue
    Li, Guangqi
    Zheng, Zheng
    Wen, Wenjuan
    Zhao, Haihui
    Liu, Xia
    Xie, Jiaping
    Han, Lin
    HEREDITARY CANCER IN CLINICAL PRACTICE, 2024, 22 (01)
  • [45] Inhibition of β-Catenin Enhances the Anticancer Effect of Irreversible EGFR-TKI in EGFR-Mutated Non-small-cell Lung Cancer with a T790M Mutation
    Togashi, Yosuke
    Hayashi, Hidetoshi
    Terashima, Masato
    de Velasco, Marco A.
    Sakai, Kazuko
    Fujita, Yoshihiko
    Tomida, Shuta
    Nakagawa, Kazuhiko
    Nishio, Kazuto
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (01) : 93 - 101
  • [46] Presence of the minor EGFR T790M mutation is associated with drug-sensitive EGFR mutations in lung adenocarcinoma patients
    Hashida, Shinsuke
    Soh, Junichi
    Toyooka, Shinichi
    Tanaka, Tomoaki
    Furukawa, Masashi
    Shien, Kazuhiko
    Yamamoto, Hiromasa
    Asano, Hiroaki
    Tsukuda, Kazunori
    Hagiwara, Koichi
    Miyoshi, Shinichiro
    ONCOLOGY REPORTS, 2014, 32 (01) : 145 - 152
  • [47] Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors
    Sun, Jong-Mu
    Ahn, Myung-Ju
    Choi, Yoon-La
    Ahn, Jin Seok
    Park, Keunchil
    LUNG CANCER, 2013, 82 (02) : 294 - 298
  • [48] Association between clinical outcome of first EGFR-TKIs and T790M mutation in NSCLC patients harboring EGFR mutation with acquired resistance to EGFR-TKIs.
    Oya, Yuko
    Yoshida, Tatsuya
    Tanaka, Kosuke
    Shimizu, Junichi
    Horio, Yoshitsugu
    Sakao, Yukinori
    Hida, Toyoaki
    Yatabe, Yasushi
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [49] Successful osimertinib treatment for leptomeningeal carcinomatosis from lung adenocarcinoma with the T790M mutation of EGFR
    Sakai, Hitomi
    Hayashi, Hidetoshi
    Iwasa, Tsutomu
    Hasegawa, Yoshikazu
    Takeda, Masayuki
    Nakagawa, Kazuhiko
    ESMO OPEN, 2017, 2
  • [50] Association between clinical outcome of first EGFR-TKIs and T790M mutation in NSCLC patients harboring EGFR mutation with acquired resistance to EGFR-TKIs
    Oya, Y.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S622 - S622
12345